+

WO1997035538A3 - Tumor necrosis factor alpha convertase - Google Patents

Tumor necrosis factor alpha convertase Download PDF

Info

Publication number
WO1997035538A3
WO1997035538A3 PCT/EP1997/001497 EP9701497W WO9735538A3 WO 1997035538 A3 WO1997035538 A3 WO 1997035538A3 EP 9701497 W EP9701497 W EP 9701497W WO 9735538 A3 WO9735538 A3 WO 9735538A3
Authority
WO
WIPO (PCT)
Prior art keywords
tnfα
con
necrosis factor
tumor necrosis
factor alpha
Prior art date
Application number
PCT/EP1997/001497
Other languages
French (fr)
Other versions
WO1997035538A2 (en
Inventor
Gerard M Mcgeehan
James David Becherer
Marcia L Moss
Frank J Schoenen
Warren J Rocque
Wen-Ji Chen
John R Didsbury
Shiow-Lian Catherine Jin
Original Assignee
Glaxo Group Ltd
Gerard M Mcgeehan
James David Becherer
Marcia L Moss
Frank J Schoenen
Warren J Rocque
Chen Wen Ji
John R Didsbury
Jin Shiow Lian Catherine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Gerard M Mcgeehan, James David Becherer, Marcia L Moss, Frank J Schoenen, Warren J Rocque, Chen Wen Ji, John R Didsbury, Jin Shiow Lian Catherine filed Critical Glaxo Group Ltd
Priority to AU22913/97A priority Critical patent/AU2291397A/en
Priority to JP9534033A priority patent/JP2000507943A/en
Priority to EP97915426A priority patent/EP0900272A2/en
Publication of WO1997035538A2 publication Critical patent/WO1997035538A2/en
Publication of WO1997035538A3 publication Critical patent/WO1997035538A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Reproductive Health (AREA)

Abstract

The present invention relates to tumor necrosis factor alpha (TNFα), and more specifically to the enzyme TNFα-convertase (TNFα-con) that can proteolytically convert TNFα precursor to mature TNFα. The present invention provides DNA sequences encoding mammalian TNFα-con and functional equivalents thereof, recombinant expression vectors comprising said DNA sequences, host cell lines comprising said expression vectors, inhibitors of TNFα-con, inhibitors modified for use as ligands for affinity purification of TNFα-con, and methods for treating diseases or conditions resulting from abnormal levels of TNFα in a mammalian subject.
PCT/EP1997/001497 1996-03-26 1997-03-25 Tumor necrosis factor alpha convertase WO1997035538A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU22913/97A AU2291397A (en) 1996-03-26 1997-03-25 Tumor necrosis factor alpha convertase
JP9534033A JP2000507943A (en) 1996-03-26 1997-03-25 Tumor necrosis factor alpha converter
EP97915426A EP0900272A2 (en) 1996-03-26 1997-03-25 Tumor necrosis factor alpha convertase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62066396A 1996-03-26 1996-03-26
US08/620,663 1996-03-26

Publications (2)

Publication Number Publication Date
WO1997035538A2 WO1997035538A2 (en) 1997-10-02
WO1997035538A3 true WO1997035538A3 (en) 1997-11-20

Family

ID=24486845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/001497 WO1997035538A2 (en) 1996-03-26 1997-03-25 Tumor necrosis factor alpha convertase

Country Status (5)

Country Link
EP (1) EP0900272A2 (en)
JP (1) JP2000507943A (en)
AU (1) AU2291397A (en)
CA (1) CA2249985A1 (en)
WO (1) WO1997035538A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180403B1 (en) * 1999-10-28 2001-01-30 Isis Pharmaceuticals Inc. Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
ATE274346T1 (en) * 1995-06-08 2004-09-15 Immunex Corp TNF-ALPHA CONVERTING ENZYME
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
US5830742A (en) * 1995-06-08 1998-11-03 Immunex Corporation TNF-α converting enzyme
US6842704B2 (en) 1998-02-04 2005-01-11 Immunex Corporation Crystalline TNF-α-converting enzyme and uses thereof
DE69936445T2 (en) * 1998-02-04 2008-04-10 Immunex Corp., Seattle CRYSTALLINE TNF-ALPHA CONVERTING ENZYME AND USE THEREOF
US6632667B1 (en) * 1999-10-28 2003-10-14 Isis Pharmaceuticals, Inc. Modulation of L-selectin shedding via inhibition of tumor necrosis factor-α converting enzyme (TACE)
US6458552B1 (en) 2000-06-06 2002-10-01 Ortho-Mcneil Pharmaceutical, Inc. Metalloprotease peptide substrates and methods
WO2002006227A1 (en) * 2000-07-18 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
US7888324B2 (en) 2001-08-01 2011-02-15 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
WO2005080560A1 (en) * 2004-02-05 2005-09-01 Warner-Lambert Company Llc Mutant tace catalytic domain
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
CA2651042A1 (en) 2006-05-05 2007-12-13 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
WO2007138236A1 (en) * 2006-05-24 2007-12-06 The University Of Birmingham Sheddase enzymes for neuron growth
CN101679979A (en) 2007-03-24 2010-03-24 基酶有限公司 Administering antisense oligonucleotides complementary to human apolipoprotein b
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
WO2010107838A1 (en) 2009-03-16 2010-09-23 Isis Pharmaceuticals, Inc. Targeting apolipoprotein b for the reduction of apolipoprotein c-iii

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000378A1 (en) * 1990-06-22 1992-01-09 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Dna sequence for a serine protease and associated items
WO1995024501A1 (en) * 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions for the inhibition of tnf formation and uses thereof
WO1996041624A1 (en) * 1995-06-08 1996-12-27 Immunex Corporation TNF-α CONVERTING ENZYME

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000378A1 (en) * 1990-06-22 1992-01-09 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Dna sequence for a serine protease and associated items
WO1995024501A1 (en) * 1994-03-07 1995-09-14 Cetus Oncology Corporation Compositions for the inhibition of tnf formation and uses thereof
WO1996041624A1 (en) * 1995-06-08 1996-12-27 Immunex Corporation TNF-α CONVERTING ENZYME

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 97, Philadelphia, PA, US; abstract no. 400580, WENNOGLE L P ET AL: "Stabilization of C5a receptor-G-protein interactions through ligand binding." XP002034338 *
BLACK R A ET AL: "A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.", NATURE (LONDON) 385 (6618). 1997. 729-733. ISSN: 0028-0836, XP002034337 *
DE BOER A H ET AL: "Affinity purification of GTPase proteins from oat root plasma membranes using biotinylated GTP.", FEBS (FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES) LETTERS 337 (3). 1994. 281-284. ISSN: 0014-5793, XP002034334 *
JOURNAL OF CELLULAR BIOCHEMISTRY 55 (3). 1994. 380-388. ISSN: 0730-2312 *
M. WILCHECK ET AL: "Affinity chromatography", METHODS IN ENZYMOLOGY, vol. 104, 1984, pages 3 - 55, XP002034333 *
MCGEEHAN G M ET AL: "REGULATION OF TUMOUR NECROSIS FACTOR-ALPHA PROCESSING BY A METALLOPROTEINASE INHIBITOR", NATURE, vol. 370, no. 6490, 18 August 1994 (1994-08-18), pages 558 - 561, XP000574095 *
MOHLER K M ET AL: "PROTECTION AGAINST A LETHAL DOSE OF ENDOTOXIN BY AN INHIBITOR OF TUMOUR NECROSIS FACTOR PROCESSING", NATURE, vol. 370, no. 6486, 21 July 1994 (1994-07-21), pages 218 - 220, XP000574714 *
MOSS M L ET AL: "Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.", NATURE (LONDON) 385 (6618). 1997. 733-736. ISSN: 0028-0836, XP002034336 *

Also Published As

Publication number Publication date
EP0900272A2 (en) 1999-03-10
WO1997035538A2 (en) 1997-10-02
AU2291397A (en) 1997-10-17
JP2000507943A (en) 2000-06-27
CA2249985A1 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
WO1997035538A3 (en) Tumor necrosis factor alpha convertase
CA2400295A1 (en) Modified factor viii
CA2249233A1 (en) Mch4 and mch5, apoptotic protease, nucleic acids encoding and methods of use
ATE195140T1 (en) PENIOPHORA PHYTASE
IL136055A0 (en) Fibroblast growth factor -19
ATE384798T1 (en) POLYPEPTIDES WITH PHYTASE ACTIVITY AND NUCLEIC ACIDS ENCODING THEM
IL193886A0 (en) Antibodies that bind to ldcam sequences
DE69833784D1 (en) POLYPEPTIDES WITH AMINOOPEPTIDASE ACTIVITY AND FOR THESE ENCODING NUCLEIC ACIDS
SI0917571T1 (en) Agouti-related gene
CA2365418A1 (en) Phosphatases with improved phytase activity
AU3802595A (en) Tripeptidyl aminopeptidase
EP0828003A3 (en) Human serine protease
Hayashi et al. Purification and characterization of arylamidase from monkey brain
AU7489098A (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
CA2252493A1 (en) .beta.-galactoside - .alpha. 2,6-sialyltransferase gene
WO1998040498A3 (en) Immunoadhesins and methods of production and use thereof
WO1998011234A3 (en) Human protein kinases
CA2198828A1 (en) Method for increasing thermostability in cellulase emzymes by removal of the cellulose binding domains
NZ334259A (en) Fibroblast growth factor homologous factor (FHFs) peptides and nucleic acids that encode them and therapeutic and diagnostic methods for cell proliferative disorders
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
AP9901461A0 (en) Purified proteins, recombinant DNA sequences and process for controlling the ripening of coffee plants.
CA2237618A1 (en) Mch3, an apoptotic protease, nucleic acids encoding and methods of use
WO2002010399A1 (en) Novel carbonyl reductase, gene thereof and method of using the same
JP5080787B2 (en) Protein modification method, nitrile hydratase maturation method, mature nitrile hydratase production method, amide compound production method using mature nitrile hydratase
JP2000262292A5 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2249985

Country of ref document: CA

Ref country code: CA

Ref document number: 2249985

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997915426

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997915426

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997915426

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载